

Robert T. Matheson, M.D.



経歴

医療機関

オレゴンメディカルリサーチセンター 1998年～現在

9495 SW Locust Street, suite G

Portland OR 97223 USA

503-245-1525

皮膚科学の臨床研究に専念するクリニックの主任研究員
400人以上の研究のための主任または副査
重症アトピー性皮膚炎の皮膚科専門医

ダーマトロジーアソシエイト 1979年～1998年

9495 SW Locust Street, suite A

Portland OR 97223

医療、外科、および美容皮膚科
1981年から臨床試験の主任研究員

臨床教授・皮膚科

オレゴン健康科学大学病院（OHSU）

メディカルライセンス

オレゴン#9795

アメリカボード・皮膚科認定医1978年

学歴：

サルズバーグ&モザルテウム大学卒 1965年

ユタ州立大学卒 数学科 B.S. 1969年

ユタ州立大学卒 医学部 M.D. 1973年

ユタ州立大学 インターン 医科学科 1973年～1974年

オレゴン健康科学大学病院 (OHSU) 皮膚科 1976年～1979年

皮膚科美容整形外科 1979年

アメリカ軍 公衆衛生部門 フェニックスインディアンメディカル 1974年

学会：

オレゴン皮膚科ソサイエティ

パシフィックノースウエスト皮膚科ソサイエティ

米国皮膚科アカデミー

オレゴン医学アソシエーション

皮膚科研究ソサイエティ

アメリカ連邦臨床研究

皮膚外科アメリカンソサイエティ

臨床研究プロフェッショナルアソシエーション

臨床研究：

Advanced Tissue Sciences

Allergan

Amgen

Anacor

Astellas

Atrix

Barrier Therapeutics

Bayer

Berlex

Boehringer Ingelheim

Bristol-Myers-Squibb

Celgene
Cellgate
Celtic
Centocor
CombinatoRx
Connetics
Corixa
Dermik
Dow
DUSA
Eli Lilly
Ferndale
Fujisawa
Galderma
Genentech
Genetics Institute
GlaxoSmithKline
Graceway
Halcygen
HanAll Biopharma
HealthPoint
Human Genome Sciences
IDEC
Immunex
Intendis
ISIS
Isolagen
Johnson & Johnson
Leo
Matrix
Medicis
MediGene
MedImmune
Merck
NanoBio
Novartis
Novum
Nycomed
Ortho McNeil
Paddock
Parke Davis

Peplin
Perrigo
Pfizer
Promius
Regeneron
Research Testing Laboratories
Rhone-Poulenc
Roche
Rorer
Schering Plough
Serono
Shionogi
Sirtris
Stiefel
Synta
Talima
Taro
Teva
Tolerx
Tolmar
Vertex
Vicept
Wyeth
XOMA

出版・参考文献：

Leonardi, C, Matheson, R, et.al. "Anti-Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis." New England Journal of Medicine, Vol 366, March 2012

Papp, K, ...Matheson, RT, et.al. "The Efficacy of Apremilast, a Phosphodiesterase-4 inhibitor in the Treatment of Moderate to Severe Psoriasis: Results of a Phase 2 Randomized Study." Accepted to The Lancet, April, 2012

Langley, R, ...Matheson, R, et.at. "Safety Profile of Intravenous and Subcutaneous Siplizumab, an Anti-CD2 Monoclonal Antibody, for the Treatment of Plaque Psoriasis: Results of Two Randomized, double-blind, Placebo Controlled Studies." International Journal of Dermatology, Vol 49, July 2010

Szeimies, RM., RT Matheson, et.al. "Topical Methyl Aminolevulinate Photodynamic Therapy Using Red Light-Emitting Diode Light for Multiple Actinic Keratoses: A

Randomized Study.” Dermatologic Surgery, Vol. 35, Issue 4 pp. 586-592, March 20, 2009.

Bissonnette R....Matheson, R., et.al. “Humanized Anti-CD2 Monoclonal Antibody Treatment of Plaque Psoriasis: Efficacy and Pharmacodynamic Results of Two Randomized, Double-Blind, Placebo-Controlled Studies of Intravenous and Subcutaneous Siplizumab.” Archives of Dermatological Research, July 2009.

Matheson, R, et.al. “Hydrocortisone Butyrate 0.1% Lotion in the Treatment of Atopic Dermatitis in Pediatric Subjects.” Journal of Drugs in Dermatology, Vol 7, March, 2008

Abramovits, W, ...RT Matheson, et.al. “An Evaluation of the Safety and Efficacy of a Non-Steroidal Cream in the Management of Mild to Moderate Atopic Dermatitis in Pediatric Subjects.”
Submitted, 2008.

Checketts, S., ...RT Matheson, et.al. “A Double-Blind, Randomized, Vehicle-Controlled Trial to Determine the Efficacy and Safety of Hydrocortisone Butyrate Lotion 0.1% in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects Aged 3 Months to Less than 18 Years.” Abstract The Journal of Drugs in Dermatology: New Methods and Techniques, February 2008.

Matheson, RT, et.al. “Humanized Anti-CD2 Monoclonal Antibody Treatment of Plaque Psoriasis: Efficacy and Pharmacodynamic Results of Randomized, Double-Blind, Placebo-Controlled Studies of Intravenous and Subcutaneous Siplizumab.” International Journal of Dermatology, August 2007.

Gordon, KB, RR Blum, KA Papp, RT Matheson, et.al. “Efficacy and Safety of Adalimumab Treatment in Patients with Moderate to Severe Psoriasis: A Double-Blind, Randomized Clinical Trial.” Psoriasis Forum, Vol. 13, No. 1, Summer 2007.

Jorizzo, J, RT Matheson, et.al. “Vehicle-Controlled, Double-Blind, Randomized Study of Imiquimod 5% Cream Allied 3 Days per Week in One or Two courses of Treatment for Actinic Keratoses on the Head.” Journal of the American Academy of Dermatology, Vol. 57, Issue 2, August 2007.

Menter, A, T Hamilton, R Matheson, et.al. “Improvements in Patient Global Assessment of Disease Severity, Plaque Psoriasis and Psoriatic Arthristis Pain, and Pruritus with Adalimumab Therapy.” International Journal of Dermatology, February 2007.

Korman, N...Matheson, R, et.al. “Dosing With 5% Imiquimod Cream 3 Times per Week for the Treatment of Actinic Keratosis. Results of Two Phase 3, Randomized, Double-

Blind, Parallel-Group Vehicle-Controlled Trials.” Archives of Dermatology, Vol 141, April, 2005

Matheson, RT, B Miller, et.al. “The Evaluation of Maintenance Therapy of Differin® Gel, 0.1 % Vs Vehicle in Subjects with Acne Vulgaris.” Archives of Dermatology, Manuscript, 2005.

Gottlieb AB, RT Matheson, et.al. “A Randomized Trial of Etanercept as Monotherapy for Psoriasis.” Arch Dermatology, Vol. 139, December 2003.

Leonardi CL, JL Powers, RT Matheson, et.al. “Multicenter Dose-Ranging Study of the Safety and Efficacy of Etanercept in Patients with Psoriasis.” New England Journal of Medicine, Vol. 349, November 2003.

Gottlieb AB, RT Matheson, et.al. “Etanercept as Monotherapy for Psoriasis.” Lancet, Research Letter, 2002.

Matheson RT, et.al. “Subcutaneous Injection of MEDI-507, an Anti-T-cell Monoclonal Antibody, for the Treatment of Psoriasis: Phase I Results.” Journal of Investigative Dermatology, Abstract. 2001;117:817.

Gottlieb AB, ...RT Matheson, et. al. “Efficacy of Etanercept in Patients with Psoriasis.” Lancet, Research Letter, 2001.

Matheson RT, et. al. “Subcutaneous Injection of MEDI-507, an Anti-T-cell Monoclonal Antibody, for the Treatment of Psoriasis: Phase I Results.” European Society for Dermatologic Research, Abstract. April, 2001.

Wolf J, ...RT Matheson, et.al. “Safety and Efficacy of Short-Duration Oral Terbinafine, in the Treatment of Tinea Corporis or Tinea Cruris in Subjects with HIV or Diabetes.” Cutis, 2001.

Wolf J, ...RT Matheson, et.al. “Randomized Trial of Oral Terbinafine for 2 or 4 Weeks in the Treatment of Tinea Pedis in Subjects with Diabetes.” American Journal of Medicine, April, 2000.

Matheson, RT (based on interview with). “Advancing the Cause of Research: What You Need to Know About Participating in a Clinical Trial.” National Psoriasis Foundation Bulletin, pp. 10-11, January, 2000.

科学展:

6th International Psoriasis Gene to Clinic, December, 2011. “Results of a Single Ascending Dose Study to Assess the Safety and Tolerability of CNTO 1959 Following IV or SC Administration in Healthy Subjects and in Subjects with Moderate to Severe Psoriasis.”

European Academy of Dermatology and Venereology, Annual Meeting, October 2011. “Secukinumab, a Novel Fully Human Antibody to Interleukin-17A, in the Treatment of Moderate-to-Severe Plaque Psoriasis: Efficacy and Safety Interim Results from a Phase II Intravenous Induction Dose-Ranging Study.” (Research supported by Novartis Pharmaceuticals.)

American Academy of Dermatology Annual Meeting, February 2011. “Safety and Bioavailability of Two Calcipotriene Formulations in subjects with Mild to Moderate Plaque-Type Psoriasis.” Poster Presentation (Research supported by Stiefel, a GSK company.)

The Congress of the Psoriasis International Network Annual Meeting, July 2010. “Sustained Efficacy of Ustekinumab for the Treatment of Moderate to Severe Psoriasis in Initial Responders Continuing with Maintenance Therapy Through Year 3.” Presentation. (Research supported by Centocor Ortho Biotech, Inc.)

American Academy of Dermatology Annual Meeting, March 2010. “Calcipotriene foam for the Treatment of Plaque-Type Psoriasis: Results of Two Phase III Studies.” (Research supported by Stiefel Laboratories.)

European Academy of Dermatology and Venereology, Annual Meeting, 2009. “AIN457 Demonstrated to be an Effective, Fast Acting Drug for the Treatment of Chronic Plaque Type Psoriasis in a Proof of Concept Trial. (Research supported by Novartis Pharmaceuticals.)

American Academy of Dermatology Annual Meeting, February 2008. “Improvements in Patient Global Assessment of Disease Severity, Plaque Psoriasis and Psoriatic Arthritis Pain, and Pain and Pruritus with Adalimumab; Subanalysis of the First 16 Weeks of Reveal.” Poster Presentation. (Research supported by Abbott Laboratories.)

American Academy of Dermatology Annual Meeting, February 2008. Checketts, S., ...RT Matheson, et.al. “A Double-Blind, Randomized, Vehicle-Controlled Trial to Determine the Efficacy and Safety of Hydrocortisone Butyrate Lotion 0.1% in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects Aged 3 Months to Less than 18 Years.” Poster Presentation. (Research supported by Therapeutics, Inc.)

8th International Congress on SLE, Shanghai May 2007. “Early Safety Results of MEDI-545, an Anti-Interferon- α Monoclonal Antibody, in Patients with Systemic Lupus

Erythematosus in the MI-CP126 Trial.” Poster Presentation. (Research supported by MedImmune, Inc.)

American Academy of Dermatology Annual Meeting, February 2007. “Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Topically Applied AN0128 1% Cream for the Treatment of Mild to Moderate Atopic Dermatitis.” Poster Presentation. (Research supported by Anacor Pharmaceuticals, Inc.)

American Academy of Dermatology Summer Meeting August 2006. “An Open Label Adrenal Suppression Study of Hydrocortisone Butyrate Lotion 0.1% Used 3. Daily in Pediatric Subjects Aged 3 Months to Less than 18 Years with Moderate to Severe Atopic Dermatitis.” Poster Presentation. (Research supported by Therapeutics, Inc.)

American Academy of Dermatology Annual Meeting, March 2006. “A Multicenter, Randomized, Double Blind, Vehicle Controlled Study of the Safety and Efficacy of Clobetasol Propionate Emulsion Formulation (EF) Foam, 0.05% in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis.” Poster Presentation. (Research supported by Connetics Corp.)

American Academy of Dermatology Annual Meeting, March 2006. “Consistency of Response of Infliximab 5mg/kg Maintenance Therapy: Data from Express and Express II.” Poster Presentation. (Research supported by Centocor, Inc.,)

American Academy of Dermatology Annual Meeting, February 2005. “Efficacy and Safety of 0.01% and 0.03% Tacrolimus Cream Versus Cream Vehicle in Mild to Moderate Atopic Dermatitis.” Poster Presentation. (Research supported by Fujisawa, Inc.)

American Academy of Dermatology Annual Meeting, February 2005. “Impact of Pimecrolimus Cream 1% on Quality of Life in Atopic Dermatitis: Results from the 6-Month, Naturalistic Nobel Study.” Poster Presentation. (Research supported by Novartis Pharmaceuticals Corp.)

World Congress of Cancers of the Skin Annual Meeting, May 2005. “Vehicle-controlled, Double-Blind Study of Imiquimod 5% Cream 3 Days per Week in 1 or 2 Courses of Treatment for Actinic Keratosis of the Head.” Poster Presentation. (Research supported by 3M Health Care)

American Academy of Dermatology Annual Meeting, February 2004. “Imiquimod 5% Cream Dosed 3 Times Weekly for the Treatment of Actinic Keratosis.” Poster Presentation. (Research supported by Therapeutics, Inc.)

American Academy of Dermatology Annual Meeting, February 2004. "Infliximab Improves Signs of Plaque Psoriasis in Patients with Psoriatic Arthritis." Poster Presentation. (Research supported by Centocor, Inc.)

American Academy of Dermatology Annual Meeting, February 2004. "The Efficacy of Infliximab in Specific Areas of the Body." Poster Presentation. (Research supported by Centocor, Inc.)

IID, Annual Meeting, April 2003. "Results of two Phase II multiple-dose trials of an anti-CD80 monoclonal antibody (IDEC-114) in Patients with Psoriasis." Abstract. (Research supported by IDEC)

American Academy of Dermatology, Annual Meeting, March, 2003. "Efficacy and Safety of Efalizumab (anti-CD11a) in Subjects with Moderate to Severe Plaques Psoriasis." Abstract. (Research supported by Genentech)

Society of Investigative Dermatology, Annual Meeting, 2002. "Efficacy of Enbrel in Patients with Psoriasis," Abstract. (Research supported by Immunex)

American Academy of Dermatology, Annual Meeting, February, 2002. "Efficacy of Etanercept in Patients with Psoriasis." Poster Presentation. (Research Supported by Immunex)

American Academy of Dermatology, Annual Meeting, March, 2001. "Therapy with Desloratadine for Chronic Idiopathic Urticaria Reduces Interference with Sleep and Daily Activities." Poster Presentation. (Research supported by Schering Plough Research Institute, Kenilworth, NJ)